Check Capital Management Inc. CA Purchases 4,775 Shares of Cardlytics, Inc. (NASDAQ:CDLX)

Check Capital Management Inc. CA boosted its position in shares of Cardlytics, Inc. (NASDAQ:CDLX) by 10.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,650 shares of the company’s stock after acquiring an additional 4,775 shares during the period. Check Capital Management Inc. CA owned 0.10% of Cardlytics worth $162,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Banco Santander S.A. purchased a new position in shares of Cardlytics during the 1st quarter valued at $199,000. Vanguard Group Inc. increased its stake in Cardlytics by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 2,211,595 shares of the company’s stock worth $32,046,000 after acquiring an additional 57,805 shares during the last quarter. Quadrature Capital Ltd bought a new position in Cardlytics in the 1st quarter worth about $1,906,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Cardlytics by 6.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,769 shares of the company’s stock valued at $432,000 after acquiring an additional 1,774 shares in the last quarter. Finally, Perbak Capital Partners LLP bought a new stake in shares of Cardlytics during the 1st quarter valued at about $2,348,000. Institutional investors own 68.10% of the company’s stock.

Cardlytics Price Performance

Cardlytics stock opened at $3.60 on Friday. The firm has a fifty day simple moving average of $3.73 and a two-hundred day simple moving average of $6.48. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.18 and a quick ratio of 1.18. Cardlytics, Inc. has a twelve month low of $2.89 and a twelve month high of $20.52.

Cardlytics (NASDAQ:CDLX) last released its earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.18. The company had revenue of $67.06 million during the quarter, compared to analyst estimates of $57.77 million. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. Cardlytics’s revenue for the quarter was down 15.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.26) EPS. On average, research analysts predict that Cardlytics, Inc. will post -1.72 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Amit Gupta sold 22,607 shares of the business’s stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of $3.85, for a total transaction of $87,036.95. Following the transaction, the chief executive officer now owns 178,519 shares in the company, valued at $687,298.15. The trade was a 11.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last 90 days, insiders sold 43,573 shares of company stock valued at $151,612. 4.40% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on CDLX shares. Craig Hallum upgraded shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th. Northland Capmk cut shares of Cardlytics from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 16th. Evercore ISI initiated coverage on shares of Cardlytics in a research report on Friday, October 11th. They issued an “in-line” rating and a $4.00 target price for the company. Lake Street Capital cut Cardlytics from a “buy” rating to a “hold” rating and reduced their target price for the company from $18.00 to $5.00 in a research note on Thursday, August 8th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Cardlytics in a research note on Thursday, November 7th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Cardlytics has a consensus rating of “Hold” and an average price target of $6.92.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.